Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16134238rdf:typepubmed:Citationlld:pubmed
pubmed-article:16134238lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0003392lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0153381lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0285558lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C1705328lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C1705341lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0034537lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0812228lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C1710082lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0879262lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:16134238lifeskim:mentionsumls-concept:C0596581lld:lifeskim
pubmed-article:16134238pubmed:issue2lld:pubmed
pubmed-article:16134238pubmed:dateCreated2005-8-30lld:pubmed
pubmed-article:16134238pubmed:abstractTextTo examine the effect of an oral fluoropyrimidine anti-cancer agent (S-1) on the radiosensitivity of a human oral cancer cell line with focusing on inhibition of survival signal, Akt/PKB. A human oral cell cancer cell line B88 was used. Activation of Akt/PKB in vivo was examined by immunohistochemistry, and apoptotic cells were detected by TUNEL method. Activation of Akt/PKB in vitro was investigated by Western blot and ELISA, and apoptotic cells were detected by Hoechst 33258 staining. S-1 (10 mg/kg/day or 50 microg/ml) greatly enhanced radiosensitivity in B88 cells by suppressing the activation of Akt/PKB. Significant increase in the percentage of apoptotic cells was observed in S-1 treated B88 cells. Survival signals Akt/PKB may be involved in determining radiosensitivity. S-1, an oral fluoropyrimidine anti-cancer agent can exert the enhancing effect on radiation by suppressing the activation of Akt/PKB.lld:pubmed
pubmed-article:16134238pubmed:languageenglld:pubmed
pubmed-article:16134238pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134238pubmed:citationSubsetIMlld:pubmed
pubmed-article:16134238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134238pubmed:statusMEDLINElld:pubmed
pubmed-article:16134238pubmed:monthAuglld:pubmed
pubmed-article:16134238pubmed:issn0304-3835lld:pubmed
pubmed-article:16134238pubmed:authorpubmed-author:YoshidaHideoHlld:pubmed
pubmed-article:16134238pubmed:authorpubmed-author:SatoMitsunobu...lld:pubmed
pubmed-article:16134238pubmed:authorpubmed-author:HaradaKojiKlld:pubmed
pubmed-article:16134238pubmed:authorpubmed-author:Supriatnolld:pubmed
pubmed-article:16134238pubmed:authorpubmed-author:KawaguchiShin...lld:pubmed
pubmed-article:16134238pubmed:authorpubmed-author:KawashimaYuic...lld:pubmed
pubmed-article:16134238pubmed:issnTypePrintlld:pubmed
pubmed-article:16134238pubmed:day26lld:pubmed
pubmed-article:16134238pubmed:volume226lld:pubmed
pubmed-article:16134238pubmed:ownerNLMlld:pubmed
pubmed-article:16134238pubmed:authorsCompleteYlld:pubmed
pubmed-article:16134238pubmed:pagination161-168lld:pubmed
pubmed-article:16134238pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:meshHeadingpubmed-meshheading:16134238...lld:pubmed
pubmed-article:16134238pubmed:year2005lld:pubmed
pubmed-article:16134238pubmed:articleTitleS-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB.lld:pubmed
pubmed-article:16134238pubmed:affiliationSecond Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan. harako@dent.tokushima-u.ac.jplld:pubmed
pubmed-article:16134238pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16134238pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16134238lld:pubmed